- Page 1 and 2:
This report is based on research co
- Page 3 and 4:
This document is in the public doma
- Page 5 and 6:
AcknowledgmentsThe authors would li
- Page 7 and 8:
ContentsExecutive Summary..........
- Page 9 and 10:
Table 17: Intra-urethral Treatment:
- Page 11 and 12:
Figure 63. Absolute Mean Change Fro
- Page 13 and 14:
associated with ED treatments. Two
- Page 15 and 16:
ED as a main complaint. In only one
- Page 17 and 18:
different formulations/modes of app
- Page 19 and 20:
Evidence Report
- Page 21 and 22:
flaccidity are no less important th
- Page 23 and 24:
prostatectomy, antipsychotic agents
- Page 25 and 26:
disease). Furthermore, there is ins
- Page 27:
Analytic FrameworkFigure 1. Analyti
- Page 30 and 31:
KQ 3. Harms of pharmaceutical treat
- Page 32 and 33:
Figure 2. Modified QUOROM Flow Char
- Page 34 and 35:
that included intervention characte
- Page 36 and 37:
Prevalence of Hypogonadism (Total S
- Page 38 and 39:
stimulation and a challenge test wi
- Page 40 and 41:
Overview of Trials79-84,86-88,90,91
- Page 42 and 43:
131,137,138,142,143,147,151,155,156
- Page 44 and 45:
pectoris occurred in a participant
- Page 46 and 47:
statistical test results for the ob
- Page 48 and 49:
individual Q1-Q15 items, 104,106,15
- Page 50 and 51:
Proportion of participants with hea
- Page 52 and 53:
erectile maintenance frequency, IIE
- Page 54 and 55:
Oral Treatments — Phosphodiestera
- Page 56 and 57:
Patients were instructed to take th
- Page 58 and 59:
Results obtained from two trials 19
- Page 60 and 61:
improved erections was higher in pa
- Page 62 and 63:
Clinically homogenous groups of pat
- Page 64 and 65:
Oral Treatments — Phosphodiestera
- Page 66 and 67:
The approximate proportion of smoke
- Page 68 and 69:
value was not reported). Even thoug
- Page 70 and 71:
Tadalafil (20 mg) versus tadalafil
- Page 72 and 73:
scheduled dosing regimen (90 percen
- Page 74 and 75:
Proportion of patients with improve
- Page 76 and 77:
Sublingual Treatments - Apomorphine
- Page 78 and 79:
been taking over the past two or fo
- Page 80 and 81:
apomorphine (5 and 6 mg: 38 and 49
- Page 82 and 83:
heterogeneity with respect to popul
- Page 84 and 85:
Finally, two studies reported on wh
- Page 86 and 87:
the second study, prolonged erectio
- Page 88 and 89:
Moxisylate versus placebo. One tria
- Page 90 and 91:
Quantitative SynthesisThere was a l
- Page 92 and 93:
erection” versus one placebo trea
- Page 94 and 95:
methods of allocation concealment.
- Page 96 and 97:
Prazosin (IU) versus placebo. One t
- Page 98 and 99:
reported adequate allocation concea
- Page 101 and 102:
Hormonal Treatments Literature Sear
- Page 103 and 104:
Harms. In the first trial, the diff
- Page 105 and 106:
sex with partner (scale 1-6, with =
- Page 107 and 108:
daily for 4 weeks followed by concu
- Page 109 and 110:
(MEDQoL) score (range 0-100) compar
- Page 111 and 112:
group (16.7, 12.5, and 8.3 percent,
- Page 113 and 114:
Question 3a. What Are the harms of
- Page 115 and 116:
Chapter 4. DiscussionThis evidence
- Page 117 and 118:
Question 1: What is the Clinical Ut
- Page 119 and 120:
Questions 2-3: What are the Benefit
- Page 121 and 122:
Harms. There were no obvious differ
- Page 123 and 124:
alone. Compared with trimix alone,
- Page 125 and 126:
PhentolamineEfficacy. The results i
- Page 127 and 128:
Question 2a-b: Do Specific Patient
- Page 129 and 130:
Methodological and Logistic Limitat
- Page 131:
Tables and Figures.Summary TablesTa
- Page 135:
123Study details 1 Study Design Set
- Page 139:
125Table 2: Prevalence of Hypogonad
- Page 143:
127Study Details 2 Study Design Set
- Page 147:
129Table 4: Prevalence of Hypogonad
- Page 151:
131Study Details 5 Study Design Set
- Page 155:
Table 7: Prevalence of Hyperprolact
- Page 159:
135StudyEDDetails 8 Study Design Se
- Page 163 and 164:
Table 10: Serious Adverse Events in
- Page 165 and 166:
Table 11: Efficacy Results of Tadal
- Page 167 and 168:
Treatment Control Relative RiskStud
- Page 169 and 170:
Treatment Control Relative RiskStud
- Page 171 and 172:
Table 14: Intracavernosal Injection
- Page 173 and 174:
StudyAdverse EventsTreatmentGroup%
- Page 175 and 176:
StudyAdverse EventsTreatment Contro
- Page 177 and 178:
Study / Typeof PatientsOutcome Defi
- Page 179 and 180:
Study ED Etiology OutcomeWilliams*1
- Page 181 and 182:
Physiologic:60.0 (18/30) 90.0 (27/3
- Page 183 and 184:
StudyAdverse EventTreatmentGroup% (
- Page 185 and 186:
TreatmentStudy ED Etiology Group% (
- Page 187 and 188:
StudyAdverse EventCavallini 1991 Pa
- Page 189 and 190:
Study/patient CharacteristicsGooma
- Page 191 and 192:
Aversa 2003Men witharteriogenicEDYa
- Page 193 and 194:
Study/patientCharacteristicsClopper
- Page 195 and 196:
Study/patientCharacteristicsOutcome
- Page 197 and 198:
Table 26: Testosterone Treatment: P
- Page 199 and 200:
McNicholas2002Patients reporting
- Page 201:
175Table 27: Miscellaneous Treatmen
- Page 205:
177Table 28: Nonarteritic Anterior
- Page 209 and 210:
Table 29: Penile Fibrosis in Studie
- Page 211 and 212:
StudyStudyDesignPatientsage range 4
- Page 213 and 214:
Figure 6. Improved erection (GEQ-Q1
- Page 215 and 216:
Figure 11. Visual disturbances (all
- Page 217 and 218:
Figure 16. Any adverse events (trea
- Page 219 and 220:
Figure 23. The mean IIEF-Q4 score:
- Page 221 and 222:
Figure 30. Improved erection (GEQ-Q
- Page 223 and 224:
Figure 37. Visual disturbances (all
- Page 225 and 226:
Figure 43. IIEF-EF ≥ 26 at follow
- Page 227 and 228:
Figure 49. Dyspepsia (all cause)Fig
- Page 229 and 230:
Figure 55. Serious adverse events (
- Page 231 and 232:
Figure 61. Mean per-patient percent
- Page 233 and 234:
Figure 67. Any adverse events (all-
- Page 235 and 236:
Figure 73. Any adverse events (all-
- Page 237 and 238:
in men with erectile dysfunction. J
- Page 239 and 240:
parameters in obese men with erecti
- Page 241 and 242:
comparative crossover study. Androl
- Page 243 and 244:
153. Shabsigh R. Efficacy of silden
- Page 245 and 246:
190.191.Stief C, Porst H, Saenz dT,
- Page 247 and 248:
treatment of men with erectile dysf
- Page 249 and 250:
randomized trial. J Urol 1997 Oct;1
- Page 251 and 252:
moderate and severe ED. Int J Impot
- Page 253 and 254:
349.350.351.randomized, placebo-con
- Page 255 and 256:
395. Moher D, Schulz KF, Altman DG.
- Page 257 and 258:
PSVRCTRIRIASBPSCSDSETTGTRTWMDpeak s
- Page 259 and 260:
dDegDept.Ff/uFHxhrHxIGMmaxminmoNANI
- Page 261 and 262:
30. or/24-2931. (ANIMALS not HUMAN)
- Page 263 and 264:
27. limit 26 to yr="1990 - 2008"28.
- Page 265 and 266:
5. exp clinical trials/6. random$.m
- Page 267 and 268:
20. or/17-1921. 16 and 2022. limit
- Page 269 and 270:
A systematic review of harms associ
- Page 271:
B-4Summary Table- Randomized Contro
- Page 274 and 275:
The Quality Assessment of Studies o
- Page 277:
AuthorFundingN; study design; eligi
- Page 281:
AuthorFundingN; study design; eligi
- Page 285:
AuthorFundingN; study design; eligi
- Page 289:
AuthorFundingN; study design; eligi
- Page 293:
C-10 AuthorFundingN; study design;
- Page 297:
C-12 AuthorFundingN; study design;
- Page 301:
C-14 AuthorFundingN; study design;
- Page 305:
C-16 AuthorFundingN; study design;
- Page 309:
C-18 AuthorFundingN; study design;
- Page 313:
C-20 AuthorFundingN; study design;
- Page 317:
C-22 AuthorFundingN; study design;
- Page 321:
C-24 AuthorFundingN; study design;
- Page 325:
C-26 AuthorFundingN; study design;
- Page 329:
C-28 AuthorFundingN; study design;
- Page 333:
C-30 AuthorFundingN; study design;
- Page 337:
C-32 AuthorFundingN; study design;
- Page 341:
C-34 AuthorFundingN; study design;
- Page 345:
C-36 AuthorFundingN; study design;
- Page 349:
C-38 AuthorFundingN; study design;
- Page 353:
C-40 AuthorFundingN; study design;
- Page 357:
C-42 AuthorFundingN; study design;
- Page 361:
C-44 AuthorFundingN; study design;
- Page 365:
C-46 AuthorFundingN; study design;
- Page 369:
C-48 AuthorFundingN; study design;
- Page 373:
C-50 AuthorFundingN; study design;
- Page 377:
C-52 AuthorFundingN; study design;
- Page 381: C-54 AuthorFundingN; study design;
- Page 385: C-56 AuthorFundingN; study design;
- Page 389: C-58 AuthorFundingN; study design;
- Page 393: C-60 AuthorFundingN; study design;
- Page 397: C-62 AuthorFundingN; study design;
- Page 401: C-64 AuthorFundingN; study design;
- Page 405: C-66 AuthorFundingN; study design;
- Page 409: C-68 AuthorFundingN; study design;
- Page 413: C-70 AuthorFundingN; study design;
- Page 417: C-72 AuthorFundingN; study design;
- Page 421: C-74 AuthorFundingN; study design;
- Page 425: C-76 AuthorFundingN; study design;
- Page 429: C-78 AuthorFundingN; study design;
- Page 435: C-81 AuthorFundingN; study design;
- Page 439: C-83 C2-Oral Vardenafil AuthorFundi
- Page 443: C-85 AuthorFundingN; study design;
- Page 447: C-87 AuthorFundingN; study design;
- Page 451: C-89 AuthorFundingN; study design;
- Page 455: C-91 AuthorFundingN; study design;
- Page 459: C-93 AuthorFundingN; study design;
- Page 463: C-95 AuthorFundingN; study design;
- Page 467: C-97 AuthorFundingN; study design;
- Page 471: C-99 AuthorFundingN; study design;
- Page 475: C-101 AuthorFundingN; study design;
- Page 479: C-103 AuthorFundingN; study design;
- Page 483:
C-105 C3-Oral Tadalafil AuthorFundi
- Page 487:
C-107 AuthorFundingN; study design;
- Page 491:
C-109 AuthorFundingN; study design;
- Page 495:
AuthorFundingN; study design; eligi
- Page 499:
C-113 AuthorFundingN; study design;
- Page 503:
C-115 AuthorFundingN; study design;
- Page 507:
C-117 AuthorFundingN; study design;
- Page 511:
C-119 AuthorFundingN; study design;
- Page 515:
C-121 AuthorFundingN; study design;
- Page 519:
C-123 AuthorFundingN; study design;
- Page 523:
C-125 AuthorFundingN; study design;
- Page 527:
C-127 AuthorFundingN; study design;
- Page 531:
C-129 AuthorFundingN; study design;
- Page 535:
C-131 AuthorFundingN; study design;
- Page 539:
C-133 AuthorFundingN; study design;
- Page 543:
C-135 F4-Apomorphine (sublingual) A
- Page 547:
C-137 AuthorFundingN; study design;
- Page 551:
C-139 AuthorFundingN; study design;
- Page 555:
C-141 AuthorFundingN; study design;
- Page 559:
C-143 AuthorFundingN; study design;
- Page 563:
AuthorFundingN; study design; eligi
- Page 567:
C-147 AuthorFundingN; study design;
- Page 571:
C-149 AuthorFundingN; study design;
- Page 575:
C-151 AuthorFundingN; study design;
- Page 579:
C-153 AuthorFundingN; study design;
- Page 583:
C-155 AuthorFundingN; study design;
- Page 587:
C-157 AuthorFundingN; study design;
- Page 591:
C-159 AuthorFundingN; study design;
- Page 595:
C-161 AuthorFundingN; study design;
- Page 599:
C-163 AuthorFundingN; study design;
- Page 603:
C-165 AuthorFundingN; study design;
- Page 607:
C-167 AuthorFundingN; study design;
- Page 611:
C-169 AuthorFundingN; study design;
- Page 615:
C-171 AuthorFundingN; study design;
- Page 619:
C-173 AuthorFundingN; study design;
- Page 623:
C-175 AuthorFundingN; study design;
- Page 627:
C-177 AuthorFundingN; study design;
- Page 631:
C-179 AuthorFundingN; study design;
- Page 635:
C-181 AuthorFundingN; study design;
- Page 639:
C-183 AuthorFundingN; study design;
- Page 643:
C-185 AuthorFundingN; study design;
- Page 647:
C-187 AuthorFundingN; study design;
- Page 651:
C-189 AuthorFundingN; study design;
- Page 655:
C-191 C6-Subcutaneous Treatment Tri
- Page 659:
C-193 AuthorFundingN; study design;
- Page 663:
C-195 C7- Intra-urethral Suppositor
- Page 667:
C-197 AuthorFundingN; study design;
- Page 671:
C-199 AuthorFundingN; study design;
- Page 675:
AuthorFundingN; study design; eligi
- Page 679:
C-203 AuthorFundingN; study design;
- Page 683:
C-205 AuthorFundingN; study design;
- Page 687:
C-207 AuthorFundingN; study design;
- Page 691:
C-209 AuthorFundingN; study design;
- Page 695:
C-211 AuthorFundingN; study design;
- Page 699:
C-213 AuthorFundingN; study design;
- Page 703:
AuthorFundingN; study design; eligi
- Page 707:
C-217 AuthorFundingN; study design;
- Page 711:
C-219 AuthorFundingN; study design;
- Page 715:
C-221 AuthorFundingN; study design;
- Page 719:
C-223 AuthorFundingN; study design;
- Page 723:
C-225 AuthorFundingN; study design;
- Page 727:
C-227 AuthorFundingN; study design;
- Page 731:
C-229 AuthorFundingN; study design;
- Page 735:
C-231 AuthorFundingN; study design;
- Page 739:
C-233 AuthorFundingN; study design;
- Page 743:
C-235 AuthorFundingN; study design;
- Page 747:
C-237 C10-Off Label Treatments Auth
- Page 751:
C-239 AuthorFundingN; study design;
- Page 755:
C-241 AuthorFundingN; study design;
- Page 759:
C-243 AuthorFundingN; study design;
- Page 763:
C-245 AuthorFundingN; study design;
- Page 767:
C-247 AuthorFundingN; study design;
- Page 771:
C-249 AuthorFundingN; study design;
- Page 775:
C-251 AuthorFundingN; study design;
- Page 779:
C-253 AuthorFundingN; study design;
- Page 783:
C-255 AuthorFundingN; study design;
- Page 787 and 788:
References(1) Abdel-Naser MB, Imam
- Page 789 and 790:
in Colombia, Ecuador, and Venezuela
- Page 791 and 792:
(67) Rendell MS, Rajfer J, Wicker P
- Page 793 and 794:
(100) Martin-Morales A, Meijide F,
- Page 795 and 796:
controlled study. Urology 2006; 68(
- Page 797 and 798:
(166) el-Saleh JC, Keogh EJ, Chew K
- Page 799 and 800:
(201) Wessells H, Levine N, Hadley
- Page 801 and 802:
with hypogonadal symptoms. Arch Gen
- Page 803 and 804:
Appendix D. Reference List of Exclu
- Page 805 and 806:
Akduman B, Crawford E D. The PCPT:
- Page 807 and 808:
Anderson R U, Wise D, Sawyer T et a
- Page 809 and 810:
Atala A, Amin M. Current concepts i
- Page 811 and 812:
Barbaree H E, Mewhort D J. The effe
- Page 813 and 814:
Bereczky Z, Bolus M, Chetty P et al
- Page 815 and 816:
Blaya C, Seganfredo A C, Dornelles
- Page 817 and 818:
Brioni J D, Moreland R B, Cowart M
- Page 819 and 820:
Campbell S F. Science, art and drug
- Page 821 and 822:
Champion H C. Erectile dysfunction
- Page 823 and 824:
Chung W S, Choi H K. Erotic erectio
- Page 825 and 826:
Crasilneck Harold B. Hypnotic techn
- Page 827 and 828:
De Leval J, Boca P, Youssef E et al
- Page 829 and 830:
Doggrell S A. Combination of finast
- Page 831 and 832:
Eardley I. Optimisation of PDE5 Inh
- Page 833 and 834:
Evans M F. Critical appraisal: Lose
- Page 835 and 836:
Formenti S C, Lieskovsky G, Simonea
- Page 837 and 838:
Garcia-Campayo Javier, Sanz-Carrill
- Page 839 and 840:
Gleave M, Qian J, Andreou C et al.
- Page 841 and 842:
Carson C C. Erectile dysfunction: E
- Page 843 and 844:
Glina S. Testosterone and erectile
- Page 845 and 846:
Kalsi J S, Bahadur G, Muneer A et a
- Page 847 and 848:
McMahon C G. New treatment options
- Page 849 and 850:
Padma-Nathan H. Efficacy and tolera
- Page 851 and 852:
Shabsigh R, Rajfer J, Aversa A et a
- Page 853 and 854:
Wincze John P, Carey Michael P. Sex
- Page 855 and 856:
Tan R S. Novel treatment options fo
- Page 857 and 858:
Gupta A, Cohen B H, Ruggieri P et a
- Page 859 and 860:
Anonymous. Sildenafil appears safe
- Page 861 and 862:
Bella A J, Brock G B. Tadalafil: A
- Page 863 and 864:
Carson C C, Burnett A L, Levine L A
- Page 865 and 866:
Curran M, Keating G. Tadalafil.[err
- Page 867 and 868:
Fagan T C, Buttler S, Marbury T et
- Page 869 and 870:
Greenstein A, Plymate S R, Katz P G
- Page 871 and 872:
Hunter R H, Joy C B, Kennedy E et a
- Page 873 and 874:
Kloner R A, Mitchell M, Emmick J T.
- Page 875 and 876:
Long R L, Sherman L S, Lombardi T J
- Page 877 and 878:
Miller N, Smolkin M E, Bissonette E
- Page 879 and 880:
Nurnberg H, George. Erectile Dysfun
- Page 881 and 882:
Porst H, Giuliano F, Glina S et al.
- Page 883 and 884:
Salonia Andrea, Briganti Alberto, M
- Page 885 and 886:
Solursh Lionel P, Solursh Diane S.
- Page 887 and 888:
van Basten J P, Van Driel M F, Hoek
- Page 889 and 890:
Yasumoto R, Nishisaka N, Sakakura T
- Page 891 and 892:
Chen J, Godschalk M F, Katz P G et
- Page 893 and 894:
Hellstrom W J. Vardenafil: a new ap
- Page 895 and 896:
Webb D J, Muirhead G J, Wulff M et
- Page 897 and 898:
Kim J M, Joh Y D, Huh J D et al. Do
- Page 899 and 900:
Tariq S H, Haleem U, Omran M L et a
- Page 901 and 902:
Aizenberg Dov, Gur Shay, Zemishlany
- Page 903 and 904:
Beretta G, Marzotto M, Zanollo A et
- Page 905 and 906:
Cheng E. Real-life safety and effic
- Page 907 and 908:
English J C, King D H C, Foley J P.
- Page 909 and 910:
Goldstein I, Auerbach S, Padma-Nath
- Page 911 and 912:
Jackson G. Sildenafil (Viagra): New
- Page 913 and 914:
Lane B Z, Ausmundson S J, Butler R
- Page 915 and 916:
McMahon C G. An attempt to standard
- Page 917 and 918:
Mulhall J P, Land S, Parker M et al
- Page 919 and 920:
Pohanka M, Kanovsky P, Bares M et a
- Page 921 and 922:
Ruof J, Graf-Morgenstern M, Mnller
- Page 923 and 924:
Sparwasser C, Treiber U, Bahren W e
- Page 925 and 926:
Wagner G, Montorsi F, Auerbach S et
- Page 927 and 928:
Anderson R A, Martin C W, Kung A W
- Page 929 and 930:
Baggaley M R, Hirst J F, Watson J P
- Page 931 and 932:
Buvat J, Boujadoue G. Testosterone
- Page 933 and 934:
Contreras L N, Masini A M, Danna M
- Page 935 and 936:
Engelhardt P F, Daha L K, Zils T et
- Page 937 and 938:
Glasser S P. Safety of PDE 5 inhibi
- Page 939 and 940:
Holtkamp M, Weissinger F, Meierkord
- Page 941 and 942:
Kirby R S. Report from London. Pros
- Page 943 and 944:
Lexchin J. New drugs with novel the
- Page 945 and 946:
Mealy N E. Avanafil. Drugs of the F
- Page 947 and 948:
Nakata M, Takashima S, Kaminou T et
- Page 949 and 950:
Phillips B G, Kato M, Pesek C A et
- Page 951 and 952:
Saad F, Grahl A S, Aversa A et al.
- Page 953 and 954:
Sipski M, Alexander C, Guo X et al.
- Page 955 and 956:
Traish A M, Goldstein I, Kim N N. T
- Page 957 and 958:
Wilt T J, Fink H A. Is antidepressa
- Page 959 and 960:
Price D E, Cooksey G, Jehu D et al.
- Page 961 and 962:
Bolona E R, Uraga M V, Haddad R M e
- Page 963 and 964:
Anonymous. Sublingual apomorphine:
- Page 965 and 966:
Bouloux P. Testim 1% testosterone g
- Page 967 and 968:
Christ B, Brockmeier D, Hauck E W e
- Page 969 and 970:
Fein R L. Classification of sexual
- Page 971 and 972:
Green B G, Martin S. Clinical asses
- Page 973 and 974:
John H, Lehmann K, Hauri D. Intraur
- Page 975 and 976:
Lee W R. The role of androgen depri
- Page 977 and 978:
Mealy N E. Alprostadil cream. Drugs
- Page 979 and 980:
Murphy J C, Srinivas S, Terris M K.
- Page 981 and 982:
Pommerville P. Drug treatments for
- Page 983 and 984:
Saie D J, Sills E S. Hyperprolactin
- Page 985 and 986:
Steidle C P, McCullough A R, Kamine
- Page 987 and 988:
Weiss J N, Badlani G H, Ravalli R e
- Page 989 and 990:
Anonymous. Study shows patients tak
- Page 991 and 992:
Bartlik Barbara D, Kaplan Peter, Ka
- Page 993 and 994:
Cawello W, Schweer H, Dietrich B et
- Page 995 and 996:
Del Popolo G, Li Marzi V, Mondaini
- Page 997 and 998:
Gallo L, Perdona S, Autorino R et a
- Page 999 and 1000:
Hofner K, Claes H, De Reijke T M et
- Page 1001 and 1002:
Kloner R A, Hutter A M, Emmick J T
- Page 1003 and 1004:
Maan Z, Arya M, Shergill I et al. P
- Page 1005 and 1006:
Montorsi F, Strambi L F, Guazzoni G
- Page 1007 and 1008:
Phelps J S, Jain A, Monga M. The Ps
- Page 1009 and 1010:
Sato Y, Suzuki N, Adachi H et al. E
- Page 1011 and 1012:
Strachan M W, Teoh W L, Don-Wauchop
- Page 1013 and 1014:
Weinhardt L S, Carey M P. Prevalenc
- Page 1015 and 1016:
Appendix E. Additional Acknowledgme
- Page 1017 and 1018:
Appendix F. Quality AssessmentRando
- Page 1019 and 1020:
AuthorYearJadad Q-1 Jadad Q-2 Jadad
- Page 1021 and 1022:
AuthorYearJadad Q-1 Jadad Q-2 Jadad
- Page 1023 and 1024:
Jadad Q-1AuthorYearJadad Q-2 Jadad
- Page 1025:
Quality Assessment of Observational
- Page 1029 and 1030:
Appendix G. Funnel PlotsSildenafilF
- Page 1031 and 1032:
Figure G-3. Sildenafil (any dose) v
- Page 1033 and 1034:
Figure G-5. Sildenafil (any dose) v
- Page 1035 and 1036:
Figure G-7. Sildenafil (any dose) v
- Page 1037 and 1038:
VardenafilAny dose vs. PlaceboFigur
- Page 1039 and 1040:
Figure G-11. Vardenafil (any dose)
- Page 1041 and 1042:
Figure G-13. Tadalafil (20 mg) vs.
- Page 1043 and 1044:
20 mg vs. 10 mgFigure G-15. Tadalaf
- Page 1045 and 1046:
Appendix H. Instruments Used in the
- Page 1047 and 1048:
1 = Very dissatisfied2 = Moderately
- Page 1049 and 1050:
Appendix I. List of Unobtained Arti